<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01330108</url>
  </required_header>
  <id_info>
    <org_study_id>SCOBA-PH</org_study_id>
    <nct_id>NCT01330108</nct_id>
  </id_info>
  <brief_title>Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension</brief_title>
  <acronym>SCOBA-PH</acronym>
  <official_title>Safely Change From Bosentan to Ambrisentan in Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the safety and tolerance of changing
      patients currently on bosentan to ambrisentan for the treatment of pulmonary arterial
      hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The therapy of pulmonary arterial hypertension (PAH) has been revolutionized with the
      development and subsequent instruction of oral endothelin receptor antagonists (ERA). The
      first approved ERA, bosentan (Tracleer, Actelion, Inc.) is an effective drug widely used
      throughout the world in the therapy of PAH. Newer ERA's, with purported advantages over the
      first approved drug have since been tested and subsequently been approved for the therapy of
      PAH in the USA and other countries including ambrisentan (Letairis, Gilead Sciences, Inc.).
      However, there is little data available on the efficacy, safety and tolerability of the
      elective change from oral bosentan to oral ambrisentan in PAH.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Not Able to Tolerate Ambrisentan</measure>
    <time_frame>baseline to 12 weeks</time_frame>
    <description>If a subject was not able tolerate ambrisentan, subject was returned to use of bosentan and ambrisentan was withdrawn within first 12 weeks of start. A subject was considered to not be able to tolerate ambrisentan if they experienced an adverse event or side effect that was not acceptable to the subject.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Distance for a Six Minute Walk at 12 Weeks Post Start of Ambrisentan</measure>
    <time_frame>baseline to 12 weeks</time_frame>
    <description>Evaluate the change in exercise tolerance. Measured the distance a subject was capable of walking in 6 minutes at basline compared to the distance at 12 weeks. The distance was measured in meters. A postive result reflects the distance increased at 12 weeks, a negative result reflects how much shorter the distance was.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Ambrisentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients currently on bosentan to ambrisentan for the treatment of pulmonary arterial hypertension.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ambrisentan</intervention_name>
    <description>ambrisentan 2.5mg, 5mg, &amp; 10mg. Daily dosage.</description>
    <arm_group_label>Ambrisentan</arm_group_label>
    <other_name>Letairis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients followed routinely in the pulmonary vascular disease clinic at the University
             of Alabama in Birmingham, greater than or equal to 19 years of age.

          2. World Health Organization (WHO) PAH Type I

          3. WHO class I-IV symptoms (no functional class exclusion).

          4. On bosentan, twice a day, with a maximum daily dose of 250mg, on a stable dose for 3
             months with no clinical indication to discontinue the drug (i.e., increased liver
             function studies or other intolerance). Patients may be on other drug therapies for
             PAH, and also may be on oxygen therapy (intermittent or continuous).

        Exclusion Criteria:

          1. Known intolerance or allergy to ambrisentan.

          2. Prior therapy with ambrisentan.

          3. Current therapy with two phosphodiesterase-5 inhibitors.

          4. Change in other approved therapy for PAH (including phosphodiesterase-5 inhibitors and
             prostanoids) within 4 weeks of baseline study visit.

          5. Planned addition of prostanoid for clinical reasons within 3 months of baseline study
             visit.

          6. Active participation in another clinical study involving the medical therapy of PAH.

          7. Uncontrolled systemic hypertension or angina pectoris

          8. Serum creatinine greater than 2.5 at or within 4 weeks of baseline.

          9. Serum liver function studies greater than 3 x normal at or within 4 weeks of baseline
             study visit.

         10. In the opinion of the investigator, a change in PAH therapy would present significant
             risk to the subject.

         11. In the opinion of the investigator, the participant is unlikely to survive for 12
             weeks after study entry.

         12. In the opinion of the investigator, the participant is likely to undergo lung or
             heart-lung transplantation within 12 weeks of study entry.

         13. A woman of childbearing potential who is not using an acceptable form of
             contraception.

         14. Pregnancy.

         15. In the opinion of the investigator, a participant who is not capable or willing to
             follow the study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert C Bourge, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univerisity of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2011</study_first_submitted>
  <study_first_submitted_qc>April 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2011</study_first_posted>
  <results_first_submitted>January 28, 2014</results_first_submitted>
  <results_first_submitted_qc>July 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 11, 2014</results_first_posted>
  <last_update_submitted>July 17, 2014</last_update_submitted>
  <last_update_submitted_qc>July 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Arterial Hypertension</keyword>
  <keyword>PAH</keyword>
  <keyword>WHO Group 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bosentan</mesh_term>
    <mesh_term>Ambrisentan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ambrisentan</title>
          <description>patients currently on bosentan to ambrisentan for the treatment of pulmonary arterial hypertension.
ambrisentan: ambrisentan 2.5mg, 5mg, &amp; 10mg. Daily dosage.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects described in baseline are those that completed the study</population>
      <group_list>
        <group group_id="B1">
          <title>Ambrisentan</title>
          <description>patients currently on bosentan to ambrisentan for the treatment of pulmonary arterial hypertension.
ambrisentan: ambrisentan 2.5mg, 5mg, &amp; 10mg. Daily dosage.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.6" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Not Able to Tolerate Ambrisentan</title>
        <description>If a subject was not able tolerate ambrisentan, subject was returned to use of bosentan and ambrisentan was withdrawn within first 12 weeks of start. A subject was considered to not be able to tolerate ambrisentan if they experienced an adverse event or side effect that was not acceptable to the subject.</description>
        <time_frame>baseline to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ambrisentan</title>
            <description>patients currently on bosentan to ambrisentan for the treatment of pulmonary arterial hypertension.
ambrisentan: ambrisentan 2.5mg, 5mg, &amp; 10mg. Daily dosage.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Not Able to Tolerate Ambrisentan</title>
          <description>If a subject was not able tolerate ambrisentan, subject was returned to use of bosentan and ambrisentan was withdrawn within first 12 weeks of start. A subject was considered to not be able to tolerate ambrisentan if they experienced an adverse event or side effect that was not acceptable to the subject.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Distance for a Six Minute Walk at 12 Weeks Post Start of Ambrisentan</title>
        <description>Evaluate the change in exercise tolerance. Measured the distance a subject was capable of walking in 6 minutes at basline compared to the distance at 12 weeks. The distance was measured in meters. A postive result reflects the distance increased at 12 weeks, a negative result reflects how much shorter the distance was.</description>
        <time_frame>baseline to 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ambrisentan</title>
            <description>patients currently on bosentan to ambrisentan for the treatment of pulmonary arterial hypertension.
ambrisentan: ambrisentan 2.5mg, 5mg, &amp; 10mg. Daily dosage.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Distance for a Six Minute Walk at 12 Weeks Post Start of Ambrisentan</title>
          <description>Evaluate the change in exercise tolerance. Measured the distance a subject was capable of walking in 6 minutes at basline compared to the distance at 12 weeks. The distance was measured in meters. A postive result reflects the distance increased at 12 weeks, a negative result reflects how much shorter the distance was.</description>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="368.71" lower_limit="190" upper_limit="510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ambrisentan</title>
          <description>patients currently on bosentan to ambrisentan for the treatment of pulmonary arterial hypertension.
ambrisentan: ambrisentan 2.5mg, 5mg, &amp; 10mg. Daily dosage.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>edema</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>lower extremity edema</sub_title>
                <description>resolved post withdrawl of drug</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>rash, not attibuted to drug</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There is bias in the study due to the fact that subjects have been proven to tolerate the initial drug in the study (bosentan) and adequate time was not allowed for subjects to be able to tolerate ambisentan</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Robert C Bourge</name_or_title>
      <organization>University of Alabama at Birmingham</organization>
      <phone>205-934-3624</phone>
      <email>bbourge@uab.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

